A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 1997 by NIH AIDS Clinical Trials Information Service.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Gilead Sciences
Collaborator:
Anderson Clinical Research
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002384
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: August 1997
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Incomplete Closed Protocol
| Condition | Intervention |
|---|---|
|
Cytomegalovirus Retinitis HIV Infections |
Drug: Cidofovir |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Vistide (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients With AIDS |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
HIV/AIDS
Drug Information available for:
Cidofovir
U.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Information not available
Contacts and Locations
No Contacts or Locations Provided
More Information
Publications:
Stagg RJ, Gathe J, Lieberman RM, Nuessle SJ, Davis JL, Ruane P, Bellman PC, Horgan M, Jaffe HS. The Vistide (cidofovir injection) treatment IND for relapsing CMV retinitis (CMV-R). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:120 (abstract no 306)
| ClinicalTrials.gov Identifier: | NCT00002384 History of Changes |
| Other Study ID Numbers: | 276A, GS-95-120, 96ACR-GIL1 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Retinitis Cytomegalovirus Retinitis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Retinal Diseases Eye Diseases |
Cytomegalovirus Infections Herpesviridae Infections DNA Virus Infections Eye Infections, Viral Eye Infections Cidofovir Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antiviral Agents Anti-Infective Agents Radiation-Sensitizing Agents Physiological Effects of Drugs Anti-HIV Agents Anti-Retroviral Agents |
ClinicalTrials.gov processed this record on May 23, 2013